thalidomide has been researched along with Histiocytosis, Sinus in 13 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Histiocytosis, Sinus: Benign, non-Langerhans-cell, histiocytic proliferative disorder that primarily affects the lymph nodes. It is often referred to as sinus histiocytosis with massive lymphadenopathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide therapy was initiated." | 2.61 | Nonresectable Thoracic Rosai-Dorfman Disease: A Case Report and Review of the Literature. ( Lin, CK; Tsai, YD, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Hoyo-Muñoz, A | 1 |
| Collado-Borrell, R | 1 |
| Escudero-Vilaplana, V | 1 |
| Bastos-Oreiro, M | 1 |
| Herranz-Alonso, A | 1 |
| Sanjurjo-Sáez, M | 1 |
| Grimaldi, M | 1 |
| Perino, F | 1 |
| Moretta, G | 1 |
| Antonelli, F | 1 |
| Paradisi, A | 1 |
| Ricci, F | 1 |
| Abeni, D | 1 |
| Didona, B | 1 |
| Fania, L | 1 |
| Lin, CK | 1 |
| Tsai, YD | 1 |
| Kalay Yildizhan, I | 1 |
| Sanli, H | 1 |
| Akay, BN | 1 |
| Erol, HM | 1 |
| Kuzu, I | 1 |
| Kırmızı, A | 1 |
| Cengiz Seval, G | 1 |
| Wei, C | 1 |
| Zhou, DB | 1 |
| Shahidi-Dadras, M | 1 |
| Hamedani, B | 1 |
| Niknezhad, N | 1 |
| Ghilizadeh, N | 1 |
| Li, X | 1 |
| Hong, Y | 1 |
| An, Q | 1 |
| Chen, J | 1 |
| Wei, H | 1 |
| Chen, HD | 1 |
| Gao, XH | 1 |
| Wang, F | 1 |
| Zhou, H | 1 |
| Luo, DQ | 1 |
| Han, JD | 1 |
| Chen, MK | 1 |
| Nadal, M | 1 |
| Kervarrec, T | 1 |
| Machet, MC | 1 |
| Petrella, T | 1 |
| Machet, L | 1 |
| Rubinstein, M | 1 |
| Assal, A | 1 |
| Scherba, M | 1 |
| Elman, J | 1 |
| White, R | 1 |
| Verma, A | 1 |
| Strakhan, M | 1 |
| Mohammadi, F | 1 |
| Janakiram, M | 1 |
| Jia, J | 1 |
| Tian, Q | 1 |
| Zhang, H | 1 |
| Zheng, Y | 1 |
| Tjiu, JW | 1 |
| Hsiao, CH | 1 |
| Tsai, TF | 1 |
| Lu, CI | 1 |
| Kuo, TT | 1 |
| Wong, WR | 1 |
| Hong, HS | 1 |
2 reviews available for thalidomide and Histiocytosis, Sinus
| Article | Year |
|---|---|
Nonresectable Thoracic Rosai-Dorfman Disease: A Case Report and Review of the Literature.
Topics: Adult; Histiocytosis, Sinus; Humans; Immunosuppressive Agents; Low Back Pain; Lower Extremity; Male; | 2019 |
Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment.
Topics: Facial Dermatoses; Female; Histiocytosis, Sinus; Humans; Immunosuppressive Agents; Middle Aged; Thal | 2003 |
11 other studies available for thalidomide and Histiocytosis, Sinus
| Article | Year |
|---|---|
Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease.
Topics: Aged; Female; Histiocytosis, Sinus; Humans; Thalidomide | 2022 |
Cutaneous Rosai-Dorfman disease after Covid 19 vaccination treated with thalidomide.
Topics: COVID-19; COVID-19 Vaccines; Histiocytosis, Sinus; Humans; Skin Diseases; Thalidomide; Vaccination | 2022 |
Rosai-Dorfman disease presenting with nasal, nodal and multiple cutaneous involvements responding to a combination of systemic steroid and low-dose thalidomide therapy.
Topics: Histiocytosis, Sinus; Humans; Nose; Skin Diseases; Steroids; Thalidomide | 2021 |
Long-time remission of laryngeal Rosai-Dorfman disease with thalidomide: a report of three cases.
Topics: Adult; Female; Histiocytosis, Sinus; Humans; Laryngeal Diseases; Larynx; Male; Remission Induction; | 2021 |
Rosai-Dorfman disease successfully treated with thalidomide: A case report.
Topics: Biopsy; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Histiocytes; Histiocytosi | 2019 |
Successful treatment of Rosai-Dorfman disease with low-dose oral thalidomide.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Follow-Up Studies; Histiocytosis, Sin | 2013 |
Dermatoscopic findings in cutaneous Rosai-Dorfman disease and response to low-dose thalidomide.
Topics: Adult; Dermoscopy; Diagnosis, Differential; Dose-Response Relationship, Drug; Facial Dermatoses; Fem | 2014 |
Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide.
Topics: Acitretin; Administration, Cutaneous; Aged; Anti-Inflammatory Agents; Breast Diseases; Clobetasol; D | 2015 |
Lenalidomide in the treatment of Rosai Dorfman disease--a first in use report.
Topics: Adult; Histiocytosis, Sinus; Humans; Immunologic Factors; Lenalidomide; Male; Thalidomide; Treatment | 2016 |
An unusual case of multiple cutaneous Rosai-Dorfman disease involving two separate parts of the body.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Arm; Biopsy, Needle; Breast; | 2017 |
Clinical and histopathologic spectrum of cutaneous Rosai-Dorfman disease in Taiwan.
Topics: Adult; Aged; Dermatologic Agents; Female; Follow-Up Studies; Histiocytosis, Sinus; Humans; Isotretin | 2004 |